Mitabor Disper (Mirtazapine)

Mirtazapine, the active ingredient in Mitabor Disper, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral tablet for oral use. It is indicated for the treatment of major depressive disorder in adult patients, where it can help improve mood, sleep quality, and appetite, and is often chosen for its dual noradrenergic and serotonergic activity. The formulation complies with European Union quality standards and is manufactured under strict Good Manufacturing Practice guidelines.

GNH USA supplies Mitabor Disper as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirtazapine acts on noradrenergic and serotonergic pathways and is primarily used for depressive disorders.

- Major depressive disorder: alleviates depressive symptoms and improves sleep and appetite in adults. - Treatment‑resistant depression: used as an adjunct when first‑line antidepressants are insufficient. - Depression with prominent anxiety: helps reduce anxiety symptoms associated with depressive episodes.

Mirtazapine may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Sedation - Increased appetite leading to weight gain - Dry mouth - Constipation - Dizziness - Orthostatic hypotension

Serious or Rare Side Effects: - Agranulocytosis - Severe neutropenia - Suicidal thoughts or behavior - Hepatic dysfunction - Severe hypersensitivity reactions - Seizures

When prescribing Mirtazapine, clinicians should consider several safety precautions.

- Assess hepatic function: evaluate liver enzymes before initiating therapy. - Monitor weight: anticipate possible weight gain and counsel patients. - Caution in elderly: increased risk of sedation and falls. - Avoid abrupt discontinuation: taper dose to reduce withdrawal symptoms. - Use cautiously in bipolar disorder: may precipitate mania. - Store at room temperature: keep in original container, protect from moisture.

Mirtazapine can interact with other medicines, affecting its safety and effectiveness.

Major Interactions (Avoid): - MAO inhibitors: concurrent use can cause serotonin syndrome. - CNS depressants (e.g., benzodiazepines, opioids): may enhance sedation and respiratory depression. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increase mirtazapine plasma levels.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): monitor for serotonin syndrome. - Anticholinergic drugs: additive dry mouth and constipation. - Warfarin: may alter INR, require monitoring. - Alcohol: can increase sedation and impair coordination. - Diuretics: may increase risk of hyponatremia.